United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
Rabin N et al. Int J Lab Hematol. 2014 Mar 27. doi: 10.1111/ijlh.12205. [Epub ahead of print].

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.
Mohty M et al. Bone Marrow Transplant. 2014 Mar 31;0. doi: 10.1038/bmt.2014.39. [Epub ahead of print]

Palliative care: a patient’s perspective.
Smith J. Int J Palliat Nurs. 2014 Apr 25;20(4):164.

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M et al. Expert Rev Anticancer Ther. 2014 May;14(5):499-510. doi: 10.1586/14737140.2014.906904. Epub 2014 Apr 17.

Holistic needs assessment in advanced, intensively treated multiple myeloma patients.
Boland EG et al. Support Care Cancer. 2014 Apr 15. [Epub ahead of print].

Semiparametric transformation models for semicompeting survival data.
Lin H et al. Biometrics. 2014 Apr 21. doi: 10.1111/biom.12178. [Epub ahead of print].

The work of living with a rare cancer: multiple myeloma.
Stephens M et al. J Adv Nurs. 2014 Apr 13. doi: 10.1111/jan.12430. [Epub ahead of print].

Clinical profiles of multiple myeloma in Asia – an Asian Myeloma Network (AMN) study.
Kim K et al. Am J Hematol. 2014 Apr 9. doi: 10.1002/ajh.23731. [Epub ahead of print].

Changes in period and cohort effects on haematological cancer mortality in Spain, 1952-2006.
Pastor-Barriuso R et al. BMC Cancer. 2014 Apr 10;14(1):250. doi: 10.1186/1471-2407-14-250.

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.
Kyle RA et al. Leukemia. 2014 Apr;28(4):980. doi: 10.1038/leu.2014.11.

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma.
Kubiczkova L et al. J Cell Mol Med. 2014 Apr 8. doi: 10.1111/jcmm.12279. [Epub ahead of print].

Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma.
Greenfield DM et al. Bone Marrow Transplant. 2014 Apr 7. doi: 10.1038/bmt.2014.63. [Epub ahead of print].

Multiple Myeloma in the Very Old: An IASIA Conference Report.
Tuchman SA et al. J Natl Cancer Inst. 2014 Apr 3. [Epub ahead of print].

Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.
Kotouńćek PP et al. Br J Haematol. 2014 Apr 2. doi: 10.1111/bjh.12873. [Epub ahead of print].

Understanding the multiple biological aspects leading to myeloma.
Boyle EM et al. Haematologica. 2014 Apr;99(4):605-12. doi: 10.3324/haematol.2013.097907.

Age disparities in survival from lymphoma and myeloma: a comparison between US and England.
Pulte D et al. Br J Haematol. 2014 Mar 29. doi: 10.1111/bjh.12837. [Epub ahead of print].

Risk adapted therapy for multiple myeloma: back to basics.
Kumar SK et al. Leuk Lymphoma. 2014 Apr 22. [Epub ahead of print].

Physical Activity in Relation to Risk of Hematologic Cancers: A Systematic Review and Meta-analysis.
Jochem C et al. Cancer Epidemiol Biomarkers Prev. 2014 Apr 4. [Epub ahead of print].

Bortezomib for the treatment of multiple myeloma.
Grosicki S et al. Expert Rev Hematol. 2014 Apr;7(2):173-85. doi: 10.1586/17474086.2014.899144.

Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
Scott LJ et al. Drugs. 2014 Apr;74(5):549-62. doi: 10.1007/s40265-014-0196-6.